Literature DB >> 3974273

Diagnosis and management of synchronous lung cancers.

M K Ferguson, T R DeMeester, J DesLauriers, A G Little, M Piraux, H Golomb.   

Abstract

The findings in 28 patients with synchronous lung cancers are reviewed. Mediastinoscopy and systemic staging were performed to exclude the possibilities that one pulmonary lesion was metastatic from the other or that both represented systemic metastases from another tumor. Nineteen patients underwent resection of both tumors. Median survival was 25 months for four patients with definite Stage I synchronous cancers (no nodal involvement; different cell types, bronchoscopically separate endobronchial lesions or arising from separate foci of carcinoma in situ) and was 27 months for seven patients with possible synchronous Stage I cancers (no nodal involvement; similar cell types; located in separate lobes). Median survival was 11 months for 16 patients having Stage II or III lung cancer accompanied by a second synchronous lung cancer. In the absence of hilar or mediastinal nodal involvement and systemic metastases, synchronous tumors should be considered separate primaries when located in different lobes, even if they have similar histologic features. Prognosis of synchronous cancers is related to the presence or absence of nodal metastases. Pneumonectomy is the operation of choice for synchronous unilateral tumors. With bilateral tumors, sequential resection starting with the most advanced lesion is appropriate. Preservation of lung tissue without compromising the cancer operation is critical.

Entities:  

Mesh:

Year:  1985        PMID: 3974273

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  32 in total

Review 1.  Microsatellite alteration in multiple primary lung cancer.

Authors:  Cheng Shen; Xin Wang; Long Tian; Guowei Che
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis.

Authors:  W A Franklin; A F Gazdar; J Haney; I I Wistuba; F G La Rosa; T Kennedy; D M Ritchey; Y E Miller
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

3.  Synchronous primary lung cancer presenting with small cell carcinoma and adenocarcinoma.

Authors:  Yoko Yamamoto; Ken Kodama; Hiroyuki Yamato; Masashi Takeda; Hiroyuki Takamori; Takahiro Karasuno
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-03-31       Impact factor: 1.520

4.  Two lung masses with different responses to pemetrexed.

Authors:  Kwang Young Park; Jae Wook Jung; Seung Bum Nam; Ho Jin Lee; Hyo Seok Kim; Yoon Hee Choi; Jae Cheol Lee
Journal:  Korean J Intern Med       Date:  2010-06-01       Impact factor: 2.884

5.  Early clinical diagnosis of synchronous multiple primary lung cancer.

Authors:  Xinying Xue; Qingliang Xue; Na Wang; Lina Zhang; Lina Guo; Xinfu Li; Junping Sun; Jianxin Wang
Journal:  Oncol Lett       Date:  2011-10-19       Impact factor: 2.967

6.  The IASLC lung cancer staging project proposal for the classification of lung cancers with multiple pulmonary sites of involvement: the first step toward finding optimal treatment.

Authors:  Samuel S Kim
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 7.  Primary cancer of the lung in women.

Authors:  E B Smith
Journal:  J Natl Med Assoc       Date:  1989-09       Impact factor: 1.798

Review 8.  Lung cancer--current concepts and controversies.

Authors:  S B Pett; J A Wernly; B F Akl
Journal:  West J Med       Date:  1986-07

9.  Synchronous double primary lung cancers via p53 pathway induced by heavy smoking.

Authors:  Cheng-Chih Lin; Chih-Feng Chian; Wann-Cherng Perng; Ming-Fang Cheng
Journal:  Ann Saudi Med       Date:  2010 May-Jun       Impact factor: 1.526

10.  Development of synchronous bilateral lung cancers after esophagectomy for esophageal cancer: report of a case.

Authors:  T Imada; H Sato; K Hasuo; A Nagano
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.